mRNA-3927 is an mRNA therapy designed to treat Propionic Acidemia in patients with mutations in PCCA or PCCB.
Detailed information about the clinical trial including eligiblity criteria, sites, and endpoints can be found on Moderna’s website or at clinicaltrials.gov
Clinical trial code: NCT05769621
mRNA-3705 is an mRNA therapy designed to treat methylmalonic acidemia (MMA) caused by MUT deficiency.
Detailed information about the clinical trial including eligiblity criteria, sites, and endpoints can be found on Moderna’s website or at clinicaltrials.gov
Clinical trial code: NCT04899310
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.